BioSpace News Archive

Fact.MR – A Market Research and Competitive Intelligence Provider: As per the insights by Fact.MR, the global contract pharmaceutical market is anticipated to grow at a CAGR of 5.9% between 2017 and 2026.

Dexcom, Inc., a global leader in real-time continuous glucose monitoring, is happy to share that people with type 1 diabetes who are 25 years of age or under may now be eligible for provincial coverage of the Dexcom G6 CGM System through Manitoba Health and Seniors Care.

NRx Pharmaceuticals, a clinical stage, biopharmaceutical company provided a safety update on ZYESAMI™ which is being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the National Institutes of Health.

Cara Therapeutics, Inc. announced that results from the KARE Phase 2 clinical trial of Oral KORSUVA™ for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis patients will be presented in a late-breaking presentation at the European Academy of Dermatology and Venereology 30th Anniversary Congress, held virtually from September 29-October 2, 2021.

Jiangsu Recbio Technology Co., Ltd. (referred to as “Recbio”) and Shenzhen Rhegen Biotechnology Co., Ltd. (referred to as “Rhegen Bio”) recently signed a joint venture agreement to establish a joint venture company “Wuhan Rhecogen Biotechnology Co., Ltd.”

Aura Biosciences today announced the appointment of Chris Primiano, J.D., as Chief Business Officer and the appointment of Antony Mattessich to its Board of Directors.

Orthofix Medical Inc . (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today provided a business update.

Data Presented at IDWeek ™ 2021 Demonstrate that ALVR109, AlloVir’s Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta

UTILITY therapeutics Ltd. announced 3 data presentations at the Infectious Disease Society of America (IDSA) IDWeek 2021, taking place virtually from September 29 - October 3, 2021.

Announcing Five Total New Development Programs for Daxdilimab (HZN-7734) and Dazodalibep (HZN-4920); Expect to Initiate New Phase 2 Trials in 2022, Bringing Total Development Programs to 27 --